1. Risk Factors for Short Survival of AMS 800 Sphincter in Modern Urological Practice Fawzy Farag, Maarten van der Doelen, and John Heesakkers. Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands.

2. INTRODUCTION &OBJECTIVES
The study aims to determine the potential factors contributing to the increasing number of revisions of AMS 800 in modern urological practice.
MATERIALS & METHODS
Data of all patients who received AMS 800 at our institute between January 2003 and June 2014 were scrutinized to determine:
Number of AMS 800 sphincters implanted
Numbers and reasons of revisions and/or explantations
Risk factors associated with potential decline in survival rates of the AMS 800 implants.
Mann Whitney U-test was used to find differences between groups, Chi-Square & Fisher exact tests were used to find relation between study variables.

3. Etiology of Incontinence (Table 2).
RESULTS
102 patients, (71±9 y) underwent 214 surgical procedures between January 2003 and June 2014 (Table 1).
Etiology of Incontinence (Table 2).
Baseline %
Adjuvant therapies 41
Endoscopic urethrotomy for urethral stricture 19 DM 17
Previous urethral surgery to correct incontinence other than AMS 800 34
Table 1- Baseline Characteristics of 102 Patients
Etiology of incontinence %
Postprostatectomy
77.5
TURP
13.7
Neurogenic
5.9
Miscellaneous
2.9
Table 2- Etiology of Incontinence

4. Reasons for Revisions / Explantations
Surgical details
102 primary- and 8 secondary AMS 800 implants
20 sphincteric explantations
84 revision of one or more components of the sphincter.
Reasons for Revisions / Explantations (Table 3)
Reasons for Revisions / Explantations %
Erosion/infection 41
Urethral atrophy 19
System malfunction
Previous urethral surgery to correct incontinence other than AMS 800 34
Table 3- Reasons for Revisions / Explantations

5. Survival of AMS 800 Sphincters and Risk factor for revision (Table 4)
Definition: Time between the date of implantation of the AMS 800 sphincter and the date of 1st revision/explantation.
This definition applies for 56 sphincters in 48 patients.
Risk factor
P-value
n=37 AMS 800
947±1002 days
n=19 AMS 800
317±332 days
0.09
Adjuvant therapy
11/37 (30%)
10/19 (53%)
Pre-AMS urethral stricture
8/37 (22%)
5/19 (26%)
0.6 DM
7/37 (19%)
0.5
Previous urethral surgery (other than AMS 800)
12/19 (63%)
0.001
Erosion-infection
2/37 (5%)
0/19 (0%)
0.4
Table 4- Survival of AMS 800 Sphincters and Risk factor for revision

6. CONCLUSIONS
The increasing rate of Pre-AMS 800 trials to treat SUI with other modalities such as slings and peri-AMS 800 administration of adjuvant therapies for prostatic carcinoma are associated with short survival rates of the AMS 800 sphincters.